Actively Recruiting
Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients
Led by The University of Texas Health Science Center, Houston · Updated on 2026-02-19
100
Participants Needed
1
Research Sites
103 weeks
Total Duration
On this page
Sponsors
T
The University of Texas Health Science Center, Houston
Lead Sponsor
T
The University of Texas Health Science Center at San Antonio
Collaborating Sponsor
AI-Summary
What this Trial Is About
The investigators propose a single-center, randomized, controlled trial to determine whether early initiation of proton pump inhibitor (PPI), pantoprazole, will decrease acute kidney injury (AKI) for trauma patients presenting with hemorrhagic shock compared to routine timing of initiation of PPI. Kidney injury will be assessed by the urinary kidney injury biomarkers, and the incidence, severity and AKI-free days within first week and major adverse kidney events (MAKE) at day 30. The specific aims of the study will be achieved by a cohort of 100 patients to receive either early(study) or routine (control) administration of pantoprazole for 2 days after the initial injury insult.
CONDITIONS
Official Title
Comparison of Early Proton Pump Inhibitor Initiation Versus Usual Care on Acute Kidney Injury in Hemorrhagic Shock Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patient 18 years of age or older
- Patient meets hemorrhagic shock criteria with hypovolemic shock from traumatic acute bleeding
- Systolic blood pressure 90 mmHg or less AND heart rate 108 or higher at emergency department presentation; OR
- Systolic blood pressure 70 mmHg or less at emergency department presentation
You will not qualify if you...
- Patients younger than 18 years
- Patients currently on renal replacement therapy
- Cardiac arrest before emergency department arrival or expected survival less than 24 hours
- History of sensitivity or allergy to proton pump inhibitors
- Patients enrolled in other trials that do not allow co-enrollment
- Patients with ongoing gastrointestinal bleeding requiring higher dose gastrointestinal prophylaxis
- Vulnerable populations such as pregnant women and prisoners
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Memorial Hermann Texas Medical Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
Y
Yafen Liang, MD
CONTACT
S
Simon Betancourt Escobar, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here